Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Sponsor
Merck Sharp & Dohme LLC (Industry)
Overall Status
Recruiting
CT.gov ID
NCT03969901
Collaborator
(none)
140
65
2
52.7
2.2
0

Study Details

Study Description

Brief Summary

The primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected gram-negative bacterial infection. Participants are expected to require hospitalization through completion of intravenous (IV) study intervention, and have at least one of the following primary infection types: hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP); complicated intra-abdominal infection (cIAI); or complicated urinary tract infection (cUTI). Participants will be randomized in a 3:1 ratio to receive IMI/REL or active control. This study will also evaluate the efficacy of IMI/REL by assessing all-cause mortality at Day 28 post-randomization, as well as clinical and microbiological response to treatment. It will also evaluate the pharmacokinetics of IMI/REL.

Condition or Disease Intervention/Treatment Phase
Phase 2/Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection
Actual Study Start Date :
Oct 8, 2019
Anticipated Primary Completion Date :
Feb 29, 2024
Anticipated Study Completion Date :
Feb 29, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: IMI/REL

Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion, once every 6 hours, for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion, once every 6 hours, for a minimum of 7 days up to a maximum of 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.

Drug: IMI/REL
Age-based dosing: 12 to <18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours 2 to <12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours 3 months to <2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours Birth to <3 month, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.
Other Names:
  • MK-7655A
  • Active Comparator: Active Control

    Participants with cIAI or cUTI will receive active control via IV infusion for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive active control via IV infusion for a minimum of 7 days up to a maximum of 14 days. All active control and oral switch medications will be administered per authorized PI, SPC, or international treatment guidelines. All active control and oral switch medications will be chosen from a list of acceptable approved agents.

    Drug: Active Control
    All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines. NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents.

    Outcome Measures

    Primary Outcome Measures

    1. Percentage of Participants With One or More Adverse Event (AE) [Up to 28 days]

      An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants with AEs will be presented.

    2. Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event (AE) [Up to 14 days]

      An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study medication due to an AE will be presented.

    Secondary Outcome Measures

    1. Number of Deaths by All Causes Through Day 28 [Up to Day 28]

      All-cause mortality up to 28 days post-randomization will be presented.

    2. Percentage of Participants With a Favorable Clinical Response at End of Therapy (EOT) [Day 5 up to Day 14]

      The percentage of participants with a favorable clinical response at EOT will be presented.

    3. Percentage of Participants With a Favorable Clinical Response at Early Follow-Up (EFU) [Day 12 up to Day 28]

      The percentage of participants with a favorable clinical response at EFU will be presented.

    4. Percentage of Participants With a Favorable Clinical Response at Late Follow-Up (LFU) [Day 19 up to Day 42]

      The percentage of participants with a favorable clinical response at LFU will be presented.

    5. Percentage of Participants With a Favorable Microbiological Response at End of Therapy (EOT) [Day 5 up to Day 14]

      The percentage of participants with a favorable microbiological response at EOT will be presented.

    6. Percentage of Participants With a Favorable Microbiological Response at End of Follow-Up (EFU) [Day 12 up to Day 28]

      The percentage of participants with a favorable microbiological response at EFU will be presented.

    7. Percentage of Participants With a Favorable Microbiological Response at Late Follow-Up (LFU) [Day 19 up to Day 42]

      Percentage of participants with a favorable microbiological response at LFU will be presented.

    8. Area Under the Curve From Time 0 to 24 Hours (AUC0-24) of Imipenem Following Administration of IMI/REL [On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.]

      Blood samples for AUC0-24 of imipenem analysis will be collected on Day 1 at 30 minutes prior to start of first dose of IV study intervention, within 10 minutes after the end of the first infusion, and 2 to 6 hours after the start of first infusion; and once at the on-therapy (OTX) visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.

    9. Area Under the Curve From Time 0 to 24 Hours (AUC0-24) of Relebactam Following Administration of IMI/REL [On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.]

      Blood samples for AUC0-24 of relebactam analysis will be collected on Day 1 at 30 minutes prior to start of first dose of IV study intervention, within 10 minutes after the end of the first infusion, and 2 to 6 hours after the start of first infusion; and once at the on-therapy (OTX) visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.

    10. Concentration at End of Infusion (Ceoi) of Imipenem Following Administration of IMI/REL [At the end of the first infusion on Day 1.]

      Blood samples for Ceoi of imipenem analysis will be collected within 10 minutes after the end of the first infusion on Day 1.

    11. Concentration at End of Infusion (Ceoi) of Relabactam Following Administration of IMI/REL [At the end of the first infusion on Day 1.]

      Blood samples for Ceoi of relabactam analysis will be collected within 10 minutes after the end of the first infusion on Day 1.

    12. Percentage of Time Imipenem Concentration Is Above Minimum Inhibitory Concentration (%T>MIC of Imipenem) Following Administration of IMI/REL [On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.]

      Blood samples for %T>MIC of imipenem analysis will be collected on Day 1 at 30 minutes prior to start of first dose of IV study intervention, within 10 minutes after the end of the first infusion, and 2 to 6 hours after the start of first infusion; and once at the on-therapy (OTX) visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 17 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Requires hospitalization and treatment with IV antibacterial therapy for confirmed or suspected gram-negative bacterial infection (in the absence of meningitis), and is expected to require hospitalization through completion of IV study intervention, with at least 1 of the following primary infection types: HABP or VABP; cIAI; or cUTI.

    • For Age Cohorts 4 and 5, participant is at least 37 weeks postmenstrual age at the time of signing the informed consent.

    • If female, must not be pregnant or breastfeeding, and at least 1 of the following conditions must apply: must not be a woman of childbearing potential (WOCBP); OR, if a WOCBP, must agree to follow contraceptive guidance during the intervention period and for at least 24 hours after the last dose of study intervention.

    • Has sufficient intravascular access to receive study drug through an existing peripheral or central line.

    Exclusion Criteria:
    • Is expected to survive less than 72 hours.

    • Has a concurrent infection that would interfere with evaluation of response to the study antibacterials (IMI/REL or Active Control), including any of the following: endocarditis; osteomyelitis; meningitis; prosthetic joint infection; active pulmonary tuberculosis; disseminated fungal infection; concomitant infection at the time of randomization that requires non-study systemic antibacterial therapy in addition to IV study treatment or oral step-down therapy.

    • Has HABP/VABP caused by an obstructive process, including lung cancer (or other malignancy metastatic to the lungs resulting in pulmonary obstruction) or other known obstruction.

    • Has a cUTI, with any of the following: complete obstruction of any portion of the urinary tract (ie, requiring a permanent indwelling urinary catheter or instrumentation); documented ileal loop reflux; suspected or confirmed perinephric or intrarenal abscess; suspected or confirmed prostatitis, urethritis, or epididymitis; trauma to pelvis/urinary tract; presence of indwelling urinary catheter which cannot be removed at study entry.

    • Has any of the following medical conditions at screening: history of a seizure disorder (requiring ongoing treatment with anti-convulsive therapy or prior treatment with anti-convulsive therapy within the last 3 years); cystic fibrosis; history of serious allergy, hypersensitivity (eg, anaphylaxis), or any serious reaction to IMI, or to any carbapenem, cephalosporin, penicillin, or other β-lactam agent, or to other β-lactamase inhibitors (eg, tazobactam, sulbactam, clavulanic acid, avibactam).

    • Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound study results, or interfere with the participant's participation for the full duration of the study.

    • If less than 3 months of age, has received more than 72 hours of empiric antibacterial treatment until meningitis has been ruled out prior to initiation of IV study intervention.

    • If 3 months of age or older, has received potentially therapeutic antibacterial therapy (eg, with gram-negative activity), including bladder infusions with topical urinary antiseptics or antibacterial agents, for a duration of more than 24 hours during the 48 hours preceding the first dose of study intervention.

    • Is anticipated to be treated with any of the following medications: valproic acid or divalproex sodium (or has used valproic acid or divalproex sodium in the 2 weeks prior to screening) through 24 hours after completion of the final dose of IV study intervention for participants who receive IMI/REL or carbapenem; concomitant IV, oral, or inhaled antimicrobial agents with gram-negative activity, in addition to those designated in the study intervention groups, during the course of all (IV/oral) study intervention; planned receipt of suppressive/prophylactic antibiotics with gram-negative activity after completion of study intervention.

    • Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 30 days prior to screening.

    • Has enrolled previously in the current study and been discontinued, or has received REL for any other reason.

    • Has an estimated creatinine clearance (based on the Cockcroft-Gault equation, for participants ≥12 years of age) or estimated glomerular filtration rate (eGFR, based on the modified Schwartz equation, for participants <12 years of age) below that specified for the appropriate age range; or requires peritoneal dialysis, hemodialysis, or hemofiltration.

    • Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 × upper limit of normal (ULN) at the time of screening. NOTE: Patients with acute hepatic failure or acute decompensation of chronic hepatic failure should also be excluded.

    • Is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence.

    • Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Banner University Medical Center ( Site 0356) Tucson Arizona United States 85724
    2 Miller Children's & Women's Hospital ( Site 0349) Long Beach California United States 90806-1737
    3 Rady Children's Hospital-San Diego ( Site 0347) San Diego California United States 92123
    4 Tufts Medical Center-Floating Hospital for Children ( Site 0350) Boston Massachusetts United States 02111
    5 University of New Mexico ( Site 0358) Albuquerque New Mexico United States 87106
    6 University Hospital ( Site 0360) San Antonio Texas United States 78229
    7 Children's Hospital of Richmond at VCU ( Site 0359) Richmond Virginia United States 23298
    8 West Virginia University Ruby Memorial Hospital ( Site 0344) Morgantown West Virginia United States 26506
    9 UMHAT Deva Maria. EOOD ( Site 0165) Burgas Bulgaria 8127
    10 MHAT City Clinic Sv. Georgi EOOD ( Site 0167) Montana Bulgaria 3400
    11 UMHAT Dr. Georgi Stranski EAD ( Site 0174) Pleven Bulgaria 5800
    12 UMHAT Kanev AD ( Site 0168) Ruse Bulgaria 7002
    13 UMHAT Kanev AD ( Site 0169) Ruse Bulgaria 7002
    14 MHAT Dr. Ival Seliminski ( Site 0173) Sliven Bulgaria 8800
    15 Fundacion Hospital San Vicente de Paul ( Site 0269) Medellin Antioquia Colombia 050010
    16 Clinica de la Costa Ltda. ( Site 0264) Barranquilla Atlantico Colombia 080020
    17 Sociedad de Cirugía de Bogotá - Hospital de San Jose ( Site 0265) Bogota Cundinamarca Colombia 1100100
    18 Fundacion Hospital Infantil Universitario de San Jose ( Site 0268) Bogota Distrito Capital De Bogota Colombia 111211
    19 Fundacion Valle del Lili ( Site 0266) Cali Valle Del Cauca Colombia 760032
    20 Hopitaux Pediatriques CHU Lenval ( Site 0143) Nice Alpes-Maritimes France 06200
    21 Hopital Francois Mitterand ( Site 0146) Dijon Cote-d Or France 21000
    22 Hopital Jeanne de Flandre ( Site 0145) Lille Nord-Pas-de-Calais France 59120
    23 Pan and Aglaia Kyriakou Children s Hospital ( Site 0247) Athens Attiki Greece 115 27
    24 University of Athens - Aghia Sophia Childrens Hospital ( Site 0243) Athens Attiki Greece 11527
    25 Hippokration General Hospital of Thessaloniki ( Site 0244) Thessaloniki Greece 546 42
    26 Debreceni Egyetem Klinikai Kozpont ( Site 0100) Debrecen Hajdu-Bihar Hungary 4032
    27 Szabolcs-Szatmar-Bereg Megyei Kórházak és Egyetemi Otatókórház-Gyermekosztály ( Site 0105) Nyiregyhaza Szabolcs-Szatmar-Bereg Hungary 4400
    28 Rambam Medical Center ( Site 0189) Haifa Israel 3109601
    29 Hadassah Ein Karem Hebrew University Medical Center ( Site 0188) Jerusalem Israel 9112001
    30 Schneider Children's Medical Center ( Site 0187) Petah Tikva Israel 4920235
    31 Chaim Sheba Medical Center ( Site 0190) Ramat Gan Israel 5262100
    32 Hospital General de Tijuana ( Site 0284) Tijuana Baja California Mexico 22000
    33 Hospital del Nino y Adolescente Morelense ( Site 0286) Emiliano Zapata Morelos Mexico 62765
    34 Centenario Hospital Miguel Hidalgo-Pediatrics Department ( Site 0290) Aguascalientes Mexico 20259
    35 Instituto Nacional de Pediatria ( Site 0291) Ciudad de Mexico Mexico 04530
    36 Haukeland Universitetssjukehus ( Site 0500) Bergen Hordaland Norway 5021
    37 University of the Philippines-Philippine General Hospital ( Site 0318) Manila National Capital Region Philippines 1000
    38 Philippine Children s Medical Center ( Site 0317) Quezon City National Capital Region Philippines 1104
    39 Wojewodzki Szpital Zespolony im. Rydgiera ( Site 0220) Torun Kujawsko-pomorskie Poland 87-100
    40 Instytut Centrum Zdrowia Matki Polki ( Site 0223) Lodz Lodzkie Poland 93-338
    41 SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 0226) Lomianki Mazowieckie Poland 05-092
    42 Pediatric Hematology Oncology and Immunology Centre n.a. D.Rogachev. ( Site 0233) Moscow Moskva Russian Federation 117197
    43 Morozovskaya Children City Clinical Hospital ( Site 0241) Moscow Moskva Russian Federation 119049
    44 State Budgetary Healthcare Institution of Novosibirsk Region City Childrens Clinical Emergency Hospi Novosibirsk Novosibirskaya Oblast Russian Federation 630011
    45 St.Petersburg State Pediatric Medical University ( Site 0236) Saint Petersburg Sankt-Peterburg Russian Federation 194100
    46 Children's City Clinical Hospital #1 ( Site 0237) Saint Petersburg Sankt-Peterburg Russian Federation 198205
    47 Children s City Clinical Hospital 5 n.a. N.F. Filatov ( Site 0235) St. Petersburg Sankt-Peterburg Russian Federation 192289
    48 Smolensk Regional Clinical Hospital ( Site 0231) Smolensk Smolenskaya Oblast Russian Federation 214018
    49 Regional Childrens Clinical Hospital ( Site 0400) Vologda Vologodskaya Oblast Russian Federation 160022
    50 Chris Hani Baragwanath Academic Hospital ( Site 0156) Johannesburg Gauteng South Africa 2013
    51 Empilweni Services and Research Unit ( Site 1557) Johannesburg Gauteng South Africa 2093
    52 Molotlegi Street ( Site 0155) Pretoria Gauteng South Africa 0208
    53 Hospital Infantil Universitario Nino Jesus ( Site 0114) Madrid Spain 28009
    54 Hospital Universitario La Paz ( Site 0113) Madrid Spain 28046
    55 Hospital Universitario Virgen del Rocio ( Site 0115) Sevilla Spain 41043
    56 Cukurova University Medical Faculty ( Site 0200) Adana Turkey 01330
    57 Ankara Universitesi Tip Fakultesi. ( Site 0202) Ankara Turkey 06590
    58 Eskisehir Osmangazi University Medical ( Site 0201) Eskisehir Turkey 26480
    59 SBU Sariyer Hamidiye Etfal Egitim ve Arastirma Hastanesi ( Site 0198) Istanbul Turkey 34453
    60 Ege Universitesi Tıp Fakultesi Hastanesi ( Site 0199) Izmir Turkey 35100
    61 SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 0121) Dnipro Dnipropetrovska Oblast Ukraine 49100
    62 PI Kryvorizka city clinical hospital 8 of Dnipropetrovsk Reg Council ( Site 0128) Kryvyy Rig Dnipropetrovska Oblast Ukraine 50082
    63 Ivano-Frankivsk Regional Children Clinical Hospital ( Site 0131) Ivano-Frankivsk Ivano-Frankivska Oblast Ukraine 76014
    64 Kharkiv City Children Hospital 16 ( Site 0130) Kharkiv Kharkivska Oblast Ukraine 61075
    65 Municipal Enterprise Children's City Clinical Hospital in Poltava City Council ( Site 0122) Poltava Poltavska Oblast Ukraine 36004

    Sponsors and Collaborators

    • Merck Sharp & Dohme LLC

    Investigators

    • Study Director: Medical Director, Merck Sharp & Dohme LLC

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Merck Sharp & Dohme LLC
    ClinicalTrials.gov Identifier:
    NCT03969901
    Other Study ID Numbers:
    • 7655A-021
    • MK-7655A-021
    • 2019-000338-20
    First Posted:
    May 31, 2019
    Last Update Posted:
    Aug 19, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 19, 2022